Analysts remain optimistic about Elevidys after Sarepta reports patient death
Shares of Sarepta Therapeutics (SRPT) are under pressure on Tuesday after the company shared a safety update related to its Elevidys, the only ...
Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the company said.
Gene-Therapy Maker Sarepta Tanks After Patient Death
Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...
Sarepta Therapeutics Hits 52-Week Low After Patient Death
Shares of Sarepta Therapeutics fell after the company said a patient with Duchenne muscular dystrophy died of liver failure after using its Elevidys treatment. The stock opened the market down 22% at ...
Health Care Flat on Rotation to Less Rate-Sensitive Sectors -- Health Care Roundup
Health-care companies' shares were flat as traders rotated into sectors that are less sensitive to shifts in interest-rate expectations. The Health and Human Services Department is weighing plans to ...
Patient death shouldn’t spell the end for Sarepta’s Elevidys, says RBC Capital
RBC Capital keeps an Outperform rating and $161 price target on Sarepta (SRPT), noting that while the news of an Elevidys patient death is ...
Investor's Business Daily on MSN19h
Sarepta's 20% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.
Sarepta stock crashed Tuesday after a patient who received its approved gene therapy, Elevidys, died due to acute liver failure.
Sarepta falls after notifying of patient death following treatment with Elevidys
Therapeutics are down 24.95, or 25%, to $76.40 in pre-market trading after the company shared a safety update related ...